Annovis Bio, Inc.ANVSNYSE
Loading
R&D Expense Growth AcceleratingAccelerating
Percentile Rank100
3Y CAGR+999.6%
5Y CAGR+236.2%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
+999.6%/yr
Annual compound
5Y CAGR
+236.2%/yr
Recent acceleration
Percentile
P100
Near historical high
vs 5Y Ago
429.4x
Strong expansion
Streak
1 yr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| 2025 | 126006.74% |
| 2024 | -48.45% |
| 2023 | 134.88% |
| 2022 | 94.78% |
| 2021 | 177.63% |
| 2020 | 293.43% |
| 2019 | 595.52% |
| 2018 | -59.17% |
| 2017 | 0.00% |